QN-302

QN‑302 is a first-in-class small molecule drug candidate developed for the treatment of pancreatic cancer and other tumors characterized by high prevalence of G‑quadruplex (G4) DNA structures. It is a tetra-substituted naphthalene diimide derivative that binds with high affinity to G4-forming sequences in the promoter regions of cancer-related genes. By stabilizing these G4 structures, QN‑302 inhibits transcription factor binding and RNA polymerase progression, leading to downregulation of oncogene expression and inhibition of tumor cell growth. Preclinical studies have demonstrated potent anti-proliferative activity in various cancer cell lines—including pancreatic ductal adenocarcinoma (PDAC)—and significant anti-tumor effects in multiple animal models. The drug has shown efficacy even in gemcitabine-resistant PDAC models and favorable safety profiles at therapeutic doses. Orphan Drug Designation has been granted by the FDA for pancreatic cancer. Early clinical data from Phase 1 trials indicate good tolerability and preliminary evidence of disease stabilization in patients with advanced or metastatic solid tumors[1][5][6][7].

Other names

2,7-bis(3-morpholinopropyl)-4-((2-(pyrrolidin-1-yl)ethyl)amino)-9-(4-(pyrrolidin-1-ylmethyl)phenyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone